SG Americas Securities LLC reduced its stake in Laboratory Corporation of America Holdings (NYSE:LH) by 4.5% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 11,773 shares of the medical research company’s stock after selling 555 shares during the quarter. SG Americas Securities LLC’s holdings in Laboratory Corporation of America were worth $1,777,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in shares of Laboratory Corporation of America by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 10,361,891 shares of the medical research company’s stock valued at $1,597,181,000 after purchasing an additional 231,600 shares during the last quarter. Boston Partners raised its position in Laboratory Corporation of America by 0.6% during the 3rd quarter. Boston Partners now owns 4,619,670 shares of the medical research company’s stock worth $697,432,000 after buying an additional 29,298 shares during the last quarter. Nordea Investment Management AB raised its position in Laboratory Corporation of America by 2.0% during the 2nd quarter. Nordea Investment Management AB now owns 2,696,851 shares of the medical research company’s stock worth $415,693,000 after buying an additional 54,100 shares during the last quarter. FMR LLC raised its position in Laboratory Corporation of America by 9.4% during the 2nd quarter. FMR LLC now owns 1,780,950 shares of the medical research company’s stock worth $274,516,000 after buying an additional 153,546 shares during the last quarter. Finally, UBS Asset Management Americas Inc. raised its position in Laboratory Corporation of America by 70.5% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 1,543,126 shares of the medical research company’s stock worth $237,857,000 after buying an additional 637,848 shares during the last quarter. 92.96% of the stock is owned by hedge funds and other institutional investors.

In other news, CEO David P. King sold 44,687 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $156.86, for a total transaction of $7,009,602.82. Following the sale, the chief executive officer now owns 258,753 shares of the company’s stock, valued at approximately $40,587,995.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Dwight Gary Gilliland sold 971 shares of the firm’s stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $153.52, for a total transaction of $149,067.92. Following the sale, the director now directly owns 3,501 shares in the company, valued at approximately $537,473.52. The disclosure for this sale can be found here. Insiders have sold a total of 178,371 shares of company stock worth $28,002,575 in the last ninety days. Corporate insiders own 0.90% of the company’s stock.

LH has been the subject of a number of recent research reports. SunTrust Banks, Inc. reissued a “buy” rating and set a $190.00 price target on shares of Laboratory Corporation of America in a research report on Thursday, October 12th. Canaccord Genuity reissued a “buy” rating and set a $180.00 price target (up from $175.00) on shares of Laboratory Corporation of America in a research report on Monday, September 11th. ValuEngine raised shares of Laboratory Corporation of America from a “hold” rating to a “buy” rating in a research report on Wednesday, September 6th. Zacks Investment Research raised shares of Laboratory Corporation of America from a “hold” rating to a “buy” rating and set a $173.00 price target for the company in a research report on Thursday, September 21st. Finally, Craig Hallum reissued a “buy” rating and set a $180.00 price target (up from $175.00) on shares of Laboratory Corporation of America in a research report on Thursday, October 26th. Seven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Laboratory Corporation of America currently has a consensus rating of “Buy” and an average price target of $168.75.

Shares of Laboratory Corporation of America Holdings (NYSE:LH) opened at $151.09 on Friday. The company has a market cap of $15,480.00, a P/E ratio of 16.25, a PEG ratio of 1.60 and a beta of 0.87. Laboratory Corporation of America Holdings has a one year low of $123.36 and a one year high of $164.22. The company has a debt-to-equity ratio of 1.18, a quick ratio of 1.75 and a current ratio of 1.89.

Laboratory Corporation of America (NYSE:LH) last issued its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.38 by $0.08. The business had revenue of $2.60 billion for the quarter, compared to analysts’ expectations of $2.55 billion. Laboratory Corporation of America had a net margin of 7.40% and a return on equity of 16.75%. The business’s revenue was up 9.5% on a year-over-year basis. During the same quarter last year, the company earned $2.25 EPS. research analysts forecast that Laboratory Corporation of America Holdings will post 9.52 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was first published by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/laboratory-corporation-of-america-holdings-lh-shares-sold-by-sg-americas-securities-llc/1727444.html.

Laboratory Corporation of America Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Institutional Ownership by Quarter for Laboratory Corporation of America (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with Analyst Ratings Network's FREE daily email newsletter.